Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria.
Adult
Biomarkers
/ urine
Calcium Oxalate
/ metabolism
Chemokine CCL2
/ metabolism
Crystallization
Female
Glomerular Filtration Rate
Humans
Hyperoxaluria, Primary
/ complications
Kidney
/ metabolism
Kidney Calculi
/ diagnosis
Male
Osteopontin
/ urine
Predictive Value of Tests
Prognosis
Renal Elimination
Renal Insufficiency, Chronic
/ diagnosis
Crystallization
Glomerular filtration rate
Monocyte-chemoattractant protein 1
Primary hyperoxaluria
Renal damage
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
received:
15
10
2019
accepted:
23
03
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
4
9
2021
Statut:
epublish
Résumé
Patients with primary hyperoxaluria (PH) often develop kidney stones and chronic kidney disease. Noninvasive urine markers reflective of active kidney injury could be useful to gauge the effectiveness of ongoing treatments. A panel of biomarkers that reflect different nephron sites and potential mechanisms of injury (clusterin, neutrophil gelatinase-associated lipocalin (NGAL), 8-isoprostane (8IP), monocyte-chemoattractant protein 1(MCP-1), liver-type fatty acid binding protein (L-FABP), heart-type fatty acid binding protein (H-FABP), and osteopontin (OPN)) were measured in 114 urine specimens from 30 PH patients over multiple visits. Generalized estimating equations were used to assess associations between biomarkers and 24 h urine excretions, calculated proximal tubular oxalate concentration (PTOx), and eGFR. Mean (±SD) age at first visit was 19.5 ± 16.6 years with an estimated glomerular filtration rate (eGFR) of 68.4 ± 21.0 ml/min/1.73m In PH patients greater urine MCP-1 and 8IP excretion might reflect ongoing collecting tubule crystallization, while greater NGAL and OPN excretion may reflect preservation of kidney mass and function. CaOx crystals, rather than oxalate ion may mediate oxidative stress in hyperoxaluric conditions. Further studies are warranted to determine whether urine MCP-1 excretion predicts long term outcome or is altered in response to treatment.
Sections du résumé
BACKGROUND
Patients with primary hyperoxaluria (PH) often develop kidney stones and chronic kidney disease. Noninvasive urine markers reflective of active kidney injury could be useful to gauge the effectiveness of ongoing treatments.
METHODS
A panel of biomarkers that reflect different nephron sites and potential mechanisms of injury (clusterin, neutrophil gelatinase-associated lipocalin (NGAL), 8-isoprostane (8IP), monocyte-chemoattractant protein 1(MCP-1), liver-type fatty acid binding protein (L-FABP), heart-type fatty acid binding protein (H-FABP), and osteopontin (OPN)) were measured in 114 urine specimens from 30 PH patients over multiple visits. Generalized estimating equations were used to assess associations between biomarkers and 24 h urine excretions, calculated proximal tubular oxalate concentration (PTOx), and eGFR.
RESULTS
Mean (±SD) age at first visit was 19.5 ± 16.6 years with an estimated glomerular filtration rate (eGFR) of 68.4 ± 21.0 ml/min/1.73m
CONCLUSION
In PH patients greater urine MCP-1 and 8IP excretion might reflect ongoing collecting tubule crystallization, while greater NGAL and OPN excretion may reflect preservation of kidney mass and function. CaOx crystals, rather than oxalate ion may mediate oxidative stress in hyperoxaluric conditions. Further studies are warranted to determine whether urine MCP-1 excretion predicts long term outcome or is altered in response to treatment.
Identifiants
pubmed: 32293313
doi: 10.1186/s12882-020-01783-z
pii: 10.1186/s12882-020-01783-z
pmc: PMC7161151
doi:
Substances chimiques
Biomarkers
0
CCL2 protein, human
0
Chemokine CCL2
0
Osteopontin
106441-73-0
Calcium Oxalate
2612HC57YE
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
133Subventions
Organisme : NIDDK NIH HHS
ID : U54 DK083908
Pays : United States
Investigateurs
Dean Assimos
(D)
Michelle Baum
(M)
Michael Somers
(M)
Lawrence Copelovitch
(L)
Prasad Devarajan
(P)
David Goldfarb
(D)
Elizabeth Harvey
(E)
Lisa Robinson
(L)
William Haley
(W)
Mini Michael
(M)
Craig Langman
(C)
Références
Kidney Int. 2006 Sep;70(5):914-23
pubmed: 16850024
Kidney Int. 2009 Jun;75(12):1264-1271
pubmed: 19225556
Kidney Int. 2012 Feb;81(4):401-6
pubmed: 21993584
Nat Rev Nephrol. 2009 Jun;5(6):310-1
pubmed: 19474825
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Urol. 1985 Dec;134(6):1242-4
pubmed: 3840540
Kidney Int. 2002 Jan;61(1):105-12
pubmed: 11786090
J Surg Res. 2014 Mar;187(1):237-43
pubmed: 24239146
J Urol. 2002 Sep;168(3):1173-81
pubmed: 12187263
Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96
pubmed: 26268910
Am J Nephrol. 2016;43(6):454-9
pubmed: 27288357
Nephron Physiol. 2004;98(2):p43-7
pubmed: 15499214
Nephrol Dial Transplant. 2012 May;27(5):1729-36
pubmed: 22547750
BJU Int. 2005 Jul;96(1):117-26
pubmed: 15963133
N Engl J Med. 2013 Aug 15;369(7):649-58
pubmed: 23944302
Urol Res. 2006 Feb;34(1):26-36
pubmed: 16397773
Urol Res. 2007 Aug;35(4):185-91
pubmed: 17541572
Clin Chim Acta. 2011 Nov 20;412(23-24):2022-30
pubmed: 21851811
Clin Cardiol. 2016 Aug;39(8):464-70
pubmed: 27175937
Annu Rev Pharmacol Toxicol. 2016;56:103-22
pubmed: 26738473
Nephrol Dial Transplant. 2003 Apr;18(4):664-9
pubmed: 12637633
BJU Int. 2006 Sep;98(3):656-60
pubmed: 16925768
Kidney Int. 2000 Oct;58(4):1492-9
pubmed: 11012884
Ann Transl Med. 2017 Jan;5(2):29
pubmed: 28217694
Clin Chim Acta. 2010 May 2;411(9-10):700-4
pubmed: 20138168
Clin J Am Soc Nephrol. 2016 Jan 7;11(1):119-26
pubmed: 26656319
Pathogens. 2013 Dec 06;2(4):636-52
pubmed: 25437337
Am J Epidemiol. 2003 Feb 15;157(4):364-75
pubmed: 12578807
Nephrol Dial Transplant. 2011 Jun;26(6):1778-85
pubmed: 21079197
Am J Kidney Dis. 2010 Nov;56(5):883-95
pubmed: 20888104
J Urol. 1997 Mar;157(3):1059-63
pubmed: 9072543
Nephrol Dial Transplant. 2012 Oct;27(10):3855-62
pubmed: 22844106
Am J Physiol Renal Physiol. 2013 Dec 1;305(11):F1574-84
pubmed: 24089413
Am J Transplant. 2018 Jan;18(1):253-257
pubmed: 28681512
Kidney Int. 2013 Nov;84(5):895-901
pubmed: 23739234